Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

August 19, 2024

Study Completion Date

January 27, 2025

Conditions
PresbyopiaNear VisionMiosisEye Diseases
Interventions
DRUG

Aceclidine+Brimonidine combination ophthalmic solution

Aceclidine+Brimonidine combination ophthalmic solution

DRUG

Aceclidine ophthalmic solution

Aceclidine ophthalmic solution

DRUG

Placebo (Vehicle) ophthalmic solution

Placebo (Vehicle) ophthalmic solution

Trial Locations (19)

Unknown

Eye Hospital, Wenzhou Medical University, Wenzhou

Beijing Tongren Hospital, Capital Medical University, Beijing

Peking University First Hospital, Beijing

The Second Xiangya Hospital of Central South University, Changsha

Ineye Hospital of Chengdu University of TCM, Chengdu

Dalian N0.3 people's hospital, Dalian

Guang Zhou Aier eye Hospital, Guangzhou

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou

The Affiliated Hospital of Guizhou Medical University, Guiyang

Affiliated Eye Hospital, Shandong University of Traditional Chinese Medicine, Jinan

Shanghai Eye Disease Prevention and Treatment Center, Shanghai

Tongji Hospital Of Tongji University, Shanghai

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School Of Medicine, Shanghai

Shanxi Eye Hospital, Taiyuan

Tianjin Eye Hospital, Tianjin

Tianjin Medical University Eye Hospital, Tianjin

Wuhan Aier Eye Hospital, Wuhan

Xi'An People's Hospital, Xi'an

Henan Eye Hospital & Henan Institute, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

LENZ Therapeutics, Inc

OTHER

lead

Corxel Pharmaceuticals

INDUSTRY

NCT06045299 - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia | Biotech Hunter | Biotech Hunter